Peptide drugs follow a regulatory pathway similar to small molecules and biologics, with additional considerations due to their hybrid nature. This guide covers the FDA (US) and EMA (EU) regulatory frameworks.
| Category | Examples | Regulatory Pathway |
|---|
| Synthetic small peptides (<50 aa) | Oxytocin, Desmopressin | NDA (FDA) / MAA (EMA) |
| Synthetic large peptides (>50 aa) | Insulin, Calcitonin | BLA (FDA) / MAA (EMA) |
| Peptide-drug conjugates | Liraglutide, Semaglutide | BLA (FDA) / MAA (EMA) |
| Modified peptides | Pegloticase, Certolizumab | BLA (FDA) / MAA (EMA) |
NDA (New Drug Application) — 21 CFR 314:
- Small synthetic peptides (<50 amino acids)
- Non-biological mechanism of action
- Chemical synthesis (SPPS or solution-phase)
BLA (Biologics License Application) — 21 CFR 601:
- Large peptides (>50 amino acids)
- Biological mechanism of action
- Recombinant or complex modification
| Deliverable | Timeline | Cost |
|---|
| Analytical characterization | 3–6 months | $50K–100K |
| GMP process development | 6–12 months | $200K–500K |
| Stability studies (ICH) | 6–12 months | $100K–300K |
| Tox lot manufacturing | 3–6 months | $100K–300K |
| Study | Duration | Purpose |
|---|
| Pharmacology (PK, PD) | 3–6 months | Efficacy rationale |
| GLP toxicology (rodent) | 3–6 months | Safety margin |
| GLP toxicology (non-rodent) | 3–6 months | Human-relevant tox |
| CMC development | 6–12 months | Manufacturing process |
Type B meeting (FDA):
- 60-day advance request
- 30-min meeting + 30-min response
- Topics: tox study design, CMC strategy, clinical plan
EMA Scientific Advice:
- Formal advice procedure
- 60-day timeline
- Binding advice from CHMP
| Section | Content | Key Elements |
|---|
| Cover letter | Administrative | Sponsor info, drug name |
| Table of contents | Summary | All sections listed |
| Introductory statement | Background | Previous studies |
| Investigator’s brochure | Nonclinical | Tox, pharmacology |
| Manufacturing information | CMC | Drug substance/product |
| Clinical protocol | Phase I plan | Design, endpoints |
| IRB information | Ethics | IRB approval |
| Investigator info | Qualifications | CV, facilities |
- FDA has 30 days to review IND
- If no clinical hold, study may proceed
- Clinical hold possible at any time
| Aspect | Details |
|---|
| Population | 20–80 healthy volunteers or patients |
| Duration | 6–12 months |
| Endpoints | Safety, tolerability, PK, PD |
| Dose | SAD (single ascending dose), MAD (multiple ascending dose) |
| Design | Randomized, double-blind, placebo-controlled |
| Aspect | Details |
|---|
| Population | 100–300 patients with target disease |
| Duration | 1–3 years |
| Endpoints | Efficacy, dose-response, safety |
| Design | Randomized, controlled, often 2–3 dose groups |
| Biomarkers | PK/PD, disease-specific markers |
| Aspect | Details |
|---|
| Population | 1000–5000+ patients |
| Duration | 2–4 years |
| Endpoints | Clinical efficacy, safety, QoL |
| Design | Randomized, double-blind, active-controlled or placebo |
| Statistics | Pre-specified analysis plan, interim analyses |
| Module | Content |
|---|
| 2.5 | Nonclinical pharmacology |
| 2.6 | Nonclinical pharmacokinetics |
| 2.7 | Human pharmacokinetics |
| 3.2.P | Drug product (CMC) |
| 3.2.S | Drug substance (CMC) |
| 5 | Clinical study reports |
| 8 | Literature references |
Similar to NDA but with:
- Expanded CMC for biological products
- Comparability studies for process changes
- Totality of evidence approach
- Standard review: 12 months from submission
- Priority review: 8 months from submission
- Accelerated approval: Variable (based on surrogate endpoints)
- Breakthrough therapy: Expedited development
Centralised procedure (mandatory for biologics):
- Submit to EMA
- Single assessment by rapporteur/co-rapporteur
- CHMP opinion → EC decision
- Timeline: 210 days (+ clock stops)
Decentralised procedure (synthetic peptides):
- Submit to one Member State (MRP) or multiple (DCP)
- National assessment + mutual recognition
- Formal advice from CHMP
- Binding opinion
- Cost: €5,000–€30,000 depending on company size
| Aspect | Synthetic Peptides | Biologics |
|---|
| Drug substance | Full characterization | Full + potency |
| Manufacturing | SPPS + HPLC purification | Cell culture + purification |
| Specifications | Identity, purity, potency | Identity, purity, potency, safety |
| Stability | ICH Q1A | ICH Q5C |
Required studies:
- Anti-drug antibody (ADA) testing in clinical studies
- Neutralizing antibody (NAb) assessment
- Impact on PK, efficacy, safety
- Risk mitigation strategies
After manufacturing process changes:
- Analytical comparability (identity, purity, potency)
- Nonclinical bridging (if needed)
- Clinical bridging (if needed)
| Requirement | Timeline | Purpose |
|---|
| Periodic safety update reports (PSUR) | Every 6 months (year 1), then annually | Safety monitoring |
| Risk evaluation and mitigation strategy (REMS) | As required | Risk management |
| Post-marketing commitment studies | Per approval | Additional data |
- Prior approval supplement: Major changes (manufacturing, indication)
- Changes being effected: Moderate changes (minor process changes)
- Annual report: Minor changes
| Pathway | FDA | EMA | Criteria |
|---|
| Fast Track | ✓ | — | Serious condition, unmet need |
| Breakthrough | ✓ | — | Substantial improvement |
| Accelerated Approval | ✓ | Conditional | Surrogate endpoint |
| Priority Review | ✓ | — | Significant improvement |
| PRIME | — | ✓ | Unmet medical need |
- Classification: GLP-1 receptor agonist (peptide analog)
- Pathway: BLA (FDA) / MAA (EMA)
- Development: 8 years (preclinical to approval)
- Key studies: SUSTAIN (T2D), STEP (obesity)
- Approval: 2017 (injectable), 2019 (oral)
- Classification: Dual GIP/GLP-1 receptor agonist
- Pathway: BLA
- Development: 7 years
- Key studies: SURPASS (T2D), SURMOUNT (obesity)
- Approval: 2022
- FDA. Guidance for Industry: Developing Biological Products. 2020.
- EMA. Guideline on the Chemistry, Quality, and Documentation of New Active Substances. CPMP/QWP/130/96.
- ICH Q1A(R2). Stability Testing of New Drug Substances and Products.
- ICH Q6B. Specifications for Biotechnological/Biological Products.
